scholarly journals Development of Graphene Oxide Nanosheets as Potential Biomaterials in Cancer Therapeutics: An In-Vitro Study against Breast Cancer Cell Line

Author(s):  
Yugal Kishore Mohanta ◽  
Kunal Biswas ◽  
Pradipta Ranjan Rauta ◽  
Debashis De ◽  
Abeer Hashem ◽  
...  

Abstract Recent advances in nanotechnology and nano biomaterials have attracted considerable attention in the field of cancer therapy. The development of biocompatible nanotherapeutics that selectively target cancer cells is a prime area of interest and current research. The use of graphene is being explored in a variety of sciences, ranging from electronics to biomedical fields. In the present study, graphene oxide nanosheets were synthesized using a modified Hummer’s method. FTIR spectroscopy, Raman spectroscopy, and X-Ray Diffraction analyses were used to characterize the as-synthesized nanosheets. FE-SEM and HR-TEM were also used to examine the structure of the as-synthesized nanosheets. Surface topography and thickness measurements were also conducted by Atomic Force Microscopy. Results indicated that the lateral thickness of the graphene nanosheets was approximately 6.45 nm, which was corroborated by the TEM and AFM analyses. Characteristic defect peaks observed in Raman spectroscopy and electron microscopy images along with the respective EDAX calculations confirmed the formation of graphene nanosheets. The potential biomedical application of graphene nanosheets was evaluated by assessing the cytotoxicity of the graphene nanosheets against human breast adenocarcinoma [MDA-MB-231] and HaCaT normal cell lines. Two different in-vitro, anti-oxidant activity assays of Graphene Oxide [GO] were employed, namely DPPH radical and the H2O2 scavenging activity. Antioxidant activity of GO was assessed in a measured concentration-dependent manner to better understand the cytotoxicity of the GO sheets in the different cell lines. The in-vitro tests revealed that the GO sheets had a high level of cytotoxicity to the human breast cancer MDA-MB-231 cells that was concentration dependent. In contrast, the cytotoxicity of the GO sheets against the HaCaT normal cell line was marginal, suggesting that the graphene nanosheets could be safely used in cancer therapy.

2018 ◽  
Vol 16 (2) ◽  
pp. 127-137
Author(s):  
Paula Sofia Coutinho Medeiros ◽  
Ana Lúcia Marques Batista de Carvalho ◽  
Cristina Ruano ◽  
Juan Carlos Otero ◽  
Maria Paula Matos Marques

Background: The impact of the ubiquitous dietary phenolic compound p-coumaric acid on human breast cancer cells was assessed, through a multidisciplinary approach: Combined biological assays for cytotoxicity evaluation and biochemical profiling by Raman microspectroscopic analysis in cells. </P><P> Methods: Para-coumaric acid was shown to exert in vitro chemoprotective and antitumor activities, depending on the concentration and cell line probed: a significant anti-invasive ability was detected for the triple-negative MDA-MB-231 cells, while a high pro-oxidant effect was found for the estrogen- dependent MCF-7 cells. A striking cell selectivity was obtained, with a more noticeable outcome on the triple-negative MDA-MB-231 cell line. Results: The main impact on the cellular biochemical profile was verified to be on proteins and lipids, thus justifying the compound´s anti-invasive effect and chemoprotective ability. Conclusion: p-Coumaric acid was thus shown to be a promising chemoprotective/chemotherapeutic agent, particularly against the low prognosis triple-negative human breast adenocarcinoma.


PLoS ONE ◽  
2013 ◽  
Vol 8 (6) ◽  
pp. e64388 ◽  
Author(s):  
Chanel E. Smart ◽  
Brian J. Morrison ◽  
Jodi M. Saunus ◽  
Ana Cristina Vargas ◽  
Patricia Keith ◽  
...  

2011 ◽  
Vol 26 (1) ◽  
pp. 105-111 ◽  
Author(s):  
Ayfer Yurt Kilcar ◽  
F. Zumrut Biber Muftuler ◽  
Perihan Unak ◽  
Cigir Biray Avci ◽  
Cumhur Gunduz

2020 ◽  
Author(s):  
Lungwani Muungo

Biodegradable nanopolymers are believed to offer great potential in cancer therapy. Here, we report thecharacterization of a novel, targeted, nanobiopolymeric conjugate based on biodegradable, nontoxic, andnonimmunogenic PMLA [poly(b-L-malic acid)]. The PMLA nanoplatform was synthesized for repetitive systemictreatments of HER2/neu-positive human breast tumors in a xenogeneic mouse model. Various moieties werecovalently attached to PMLA, including a combination of morpholino antisense oligonucleotides (AON) directedagainst HER2/neu mRNA, to block new HER2/neu receptor synthesis; anti-HER2/neu antibody trastuzumab(Herceptin), to target breast cancer cells and inhibit receptor activity simultaneously; and transferrin receptorantibody, to target the tumor vasculature and mediate delivery of the nanobiopolymer through the hostendothelial system. The results of the study showed that the lead drug tested significantly inhibited the growth ofHER2/neu-positive breast cancer cells in vitro and in vivo by enhanced apoptosis and inhibition of HER2/neureceptor signaling with suppression of Akt phosphorylation. In vivo imaging analysis and confocal microscopydemonstrated selective accumulation of the nanodrug in tumor cells via an active delivery mechanism. Systemictreatment of human breast tumor-bearing nude mice resulted in more than 90% inhibition of tumor growth andtumor regression, as compared with partial (50%) tumor growth inhibition in mice treated with trastuzumab orAON, either free or attached to PMLA. Our findings offer a preclinical proof of concept for use of the PMLAnanoplatform for combination cancer therapy.


Sign in / Sign up

Export Citation Format

Share Document